Clinical Trial

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-05-07; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-07-20
Trial Details
NCT Number NCT06974110
Lead Sponsor MOMA Therapeutics
Conditions Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer, Colorectal Cancer, Gastric Cancer, dMMR Cancer
Enrollment 132 participants
Start Date 2025-07-16
Primary Completion 2027-11 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-23